Glenview State Bank Trust DEPT. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.9% during the second quarter, Holdings Channel reports. The institutional investor owned 70,814 shares of the company’s stock after selling 650 shares during the period. Johnson & Johnson accounts for approximately 4.8% of Glenview State Bank Trust DEPT.’s holdings, making the stock its 2nd largest position. Glenview State Bank Trust DEPT.’s holdings in Johnson & Johnson were worth $9,368,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of JNJ. Lenox Wealth Advisors Inc. increased its stake in shares of Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after buying an additional 5 shares in the last quarter. Lbmc Investment Advisors LLC increased its stake in shares of Johnson & Johnson by 0.4% in the first quarter. Lbmc Investment Advisors LLC now owns 3,704 shares of the company’s stock valued at $461,000 after buying an additional 14 shares in the last quarter. Berson & Corrado Investment Advisors LLC increased its stake in shares of Johnson & Johnson by 0.7% in the first quarter. Berson & Corrado Investment Advisors LLC now owns 2,835 shares of the company’s stock valued at $353,000 after buying an additional 19 shares in the last quarter. Cascade Investment Advisors Inc. increased its stake in shares of Johnson & Johnson by 0.3% in the second quarter. Cascade Investment Advisors Inc. now owns 7,048 shares of the company’s stock valued at $932,000 after buying an additional 23 shares in the last quarter. Finally, RB Capital Management LLC increased its stake in shares of Johnson & Johnson by 0.4% in the first quarter. RB Capital Management LLC now owns 5,559 shares of the company’s stock valued at $692,000 after buying an additional 24 shares in the last quarter. Institutional investors and hedge funds own 66.06% of the company’s stock.

Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.01% during midday trading on Friday, reaching $133.10. The company’s stock had a trading volume of 4,270,571 shares. The stock has a market capitalization of $357.24 billion, a PE ratio of 22.52 and a beta of 0.78. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $137.08. The stock has a 50-day moving average price of $133.09 and a 200 day moving average price of $126.30.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.04. The business had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the previous year, the company posted $1.74 earnings per share. Equities analysts forecast that Johnson & Johnson will post $7.18 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be paid a $0.84 dividend. The ex-dividend date is Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.52%. Johnson & Johnson’s payout ratio is presently 56.76%.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.dailypolitical.com/2017/08/12/johnson-johnson-jnj-shares-sold-by-glenview-state-bank-trust-dept.html.

Several analysts have recently issued reports on the company. UBS AG restated a “buy” rating and issued a $136.00 price objective on shares of Johnson & Johnson in a research report on Monday, May 15th. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $132.33 price objective on the stock in a research report on Thursday, May 18th. Stifel Nicolaus restated a “hold” rating and issued a $128.00 price objective (up from $124.00) on shares of Johnson & Johnson in a research report on Thursday, May 18th. BidaskClub upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th. Finally, Wells Fargo & Company restated a “market perform” rating and issued a $135.00 price objective (up from $132.00) on shares of Johnson & Johnson in a research report on Thursday, July 6th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $133.72.

In other news, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the transaction, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now owns 226,693 shares in the company, valued at $30,993,466.96. The disclosure for this sale can be found here. Insiders own 0.19% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.